Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation

Kiran Shekar1*, Jason A Roberts2, Charles I Mcdonald1, Stephanie Fisquet1, Adrian G Barnett3, Daniel V Mullany1, Sussan Ghassabian4, Steven C Wallis2, Yoke L Fung1, Maree T Smith4 and John F Fraser1

Abstract

Introduction: Extracorporeal membrane oxygenation (ECMO) is a supportive therapy, with its success dependent on effective drug therapy that reverses the pathology and/or normalizes physiology. However, the circuit that sustains life can also sequester life-saving drugs, thereby compromising the role of ECMO as a temporary support device. This ex vivo study was designed to determine the degree of sequestration of commonly used antibiotics, sedatives and analgesics in ECMO circuits.

Methods: Four identical ECMO circuits were set up as per the standard protocol for adult patients on ECMO. The circuits were primed with crystalloid and albumin, followed by fresh human whole blood, and were maintained at a physiological pH and temperature for 24 hours. After baseline sampling, fentanyl, morphine, midazolam, meropenem and vancomycin were injected into the circuit at therapeutic concentrations. Equivalent doses of these drugs were also injected into four polyvinylchloride jars containing fresh human whole blood for drug stability testing. Serial blood samples were collected from the ECMO circuits and the controls over 24 hours and the concentrations of the study drugs were quantified using validated assays.

Results: Four hundred samples were analyzed. All study drugs, except meropenem, were chemically stable. The average drug recoveries from the ECMO circuits and the controls at 24 hours relative to baseline, respectively, were fentanyl 3% and 82%, morphine 103% and 97%, midazolam 13% and 100%, meropenem 20% and 42%, vancomycin 90% and 99%. There was a significant loss of fentanyl (p = 0.0005), midazolam (p = 0.01) and meropenem (p = 0.006) in the ECMO circuit at 24 hours. There was no significant circuit loss of vancomycin at 24 hours (p = 0.26).

Conclusions: Sequestration of drugs in the circuit has implications on both the choice and dosing of some drugs prescribed during ECMO. Sequestration of lipophilic drugs such as fentanyl and midazolam appears significant and may in part explain the increased dosing requirements of these drugs during ECMO. Meropenem sequestration is also problematic and these data support a more frequent administration during ECMO.

Introduction

Extracorporeal membrane oxygenation (ECMO) is increasingly being used in adult patients with cardiac or respiratory failure refractory to conventional therapy or with both. ECMO can be an effective bridge to recovery, clinical decision-making, long-term mechanical cardiac support, and, less commonly, heart/lung transplantation [1]. Patients on ECMO receive multiple drugs that include sedatives and analgesics, antibiotics, anticoagulants, and vasoactive agents. The success of ECMO may rely on the successful use of these therapies. Although sedatives and vasoactive agents can be titrated to effect clinically, there are no reliable clinical markers to guide antibiotic therapy in critically ill patients. Antibiotics are commonly prescribed in patients on ECMO, and suboptimal therapy may result in therapeutic failure [2-5],...
adversely affecting patient outcomes. Despite the available endpoints for titration of sedation and analgesia in the intensive care unit [6] and efforts to minimize sedative drug use in this group [7], studies have reported escalating sedative doses over time in patients on ECMO [8-10].

There are limited data to guide drug therapy in adult patients receiving ECMO. Data from neonatal circuit experiments reveal significant sequestration of drugs in the ECMO circuit [11,12], and the extent of loss depends upon their physicochemical properties, type and age of the circuit, and the pumps used [10,13]. Pharmacokinetic (PK) studies in neonates [11,12] have consistently demonstrated increased volume of distribution (Vd) and decreased drug clearance (CL) during ECMO. Sequestration of drugs in the circuit appears to add to the increased Vd along with other factors related to critical illness, such as third spacing [11,14]. These studies in neonates highlight the important issue of altered PK during ECMO, but further extrapolation of the neonatal data to adult intensive care practice may not be relevant given the developmental and physiological differences between the two populations [15]. Systematic research in this area by using contemporary circuitry is required to develop evidence-based dosing guidelines for antibiotic therapy in adult patients receiving ECMO. The aim of this study was to describe the disposition of the analgesics fentanyl and morphine, the sedative agent midazolam, and the antibiotics meropenem and vancomycin in an ex vivo ECMO circuit model.

Materials and methods
Ethics approval was obtained from the local Human Research Ethics Committee (HREC/12/QPCH/90).

Extracorporeal membrane oxygenation circuits
The methods for the development of our ex vivo model of ECMO have been published previously [16]. Four permanent life support (PLS) ECMO circuits (Maquet Cardiopulmonary AG, Rastatt, Germany) were used. Each circuit consisted of Bioline tubing™, a PLS Quadrox D oxygenator, and RotaFlow pump head. A reservoir bladder (R-38; Medtronic Pty Ltd, Minneapolis, MN, USA) was added to allow fluid sampling from the closed circuit. The circuits were primed with 900 mL of Plasmalyte P-148 (Baxter Healthcare, Toongabbie, New South Wales, Australia) and then exchanged for 500 mL of Albumex 4 (Human Albumin 40 g/L; CSL Limited, Broadmeadows, Victoria, Australia). Porcine mucous heparin (Pfizer Australia, West Ryde, New South Wales, Australia) was added to the circuits (5,000 U). Fresh whole human blood (less than 5 days old, mean volume of 420 ± 52 mL, provided by Australian Red Cross Blood Service, Melbourne, Victoria, Australia) was used for the final prime, and the circuits were pressurized to obtain post-oxygenator pressures of 230 to 250 mm Hg.

The final volume of the pressurized circuit was 668 ± 1.7 mL, and the mean hemoglobin value was 64 ± 13 g/L. The mean total protein and albumin concentration in the circuit were 33 ± 2.5 g/L and 25 ± 0.9 g/L, respectively. Activated clotting time was maintained between 220 and 250 seconds. A centrifugal pump (Jostra RotaFlow; Maquet Cardiopulmonary AG) was used to maintain a circuit flow rate of 4 to 5 L/minute. Oxygen tension in the circuit blood was maintained between 150 and 200 mm Hg. Circuit temperature was maintained at 37°C. Carbon dioxide gas or sodium bicarbonate solution was added to the circuit to maintain the pH of the circulating blood in the range of 7.25 to 7.55. Fentanyl (20 μg), morphine (100 μg), midazolam (100 μg), meropenem (10 mg), vancomycin (40 mg), propofol (1 mg), dexametomidine (5 μg), thiopentone (20 mg), ceftriaxone (50 mg), linezolid (10 mg), ciprofloxacin (5 mg), fluconazole (10 mg), and caspofungin (5 mg) were injected post-oxygenator as a single bolus. The drugs with known incompatibilities to study drugs (for example, gentamicin and ticarcillin/clavulinate) were excluded. These bolus doses were selected to produce concentrations similar to clinical concentrations. Larger doses were used for the drugs that exhibit high protein binding.

Controls
Four polyvinylchloride jars with tight caps were filled with 50 mL of fresh human whole blood. Unfractionated heparin (500 U) was added to the jars for anticoagulation. Fentanyl (1.5 μg), morphine (7.5 μg), midazolam (7.5 μg), meropenem (0.75 mg), vancomycin (3 mg), propofol (75 μg), dexametomidine (0.375 μg), thiopentone (1.5 mg), ceftriaxone (3.75 mg), linezolid (0.75 mg), ciprofloxacin (0.375 mg), fluconazole (0.75 mg), and caspofungin (0.375 mg) were added to the control jars after collection of baseline blood samples. These amounts were chosen in order to produce study drug concentrations that were similar to those achieved in the ECMO circuit. The jars were then placed in an incubator at 37°C and rocked continuously to ensure even distribution of the drugs.

Blood sample collection
Post-oxygenator blood was collected into lithium heparin tubes (5 mL) at baseline and at 2, 5, 15, 30, 60, 120, and 360 minutes and at 12 and 24 hours after addition of the drugs to the circuit. Blood samples (5 mL) were also obtained from the control jars at time intervals identical to that of the circuit. All blood samples were stored on ice and centrifuged (10 minutes at 3,000g), and the plasma was separated and stored in clean pre-labeled polypropylene cryogenic vials and stored at -80°C until analysis.
Measurement of drugs in plasma samples

An on-line solid-phase extraction (SPE) Symbiosis Pharma system (Spark Holland, Emmen, The Netherlands) was used to extract the analytes of interest (fentanyl, morphine, and midazolam) and two internal standards (morphine-d3 and 1-hydroxymidazolam-d5) from plasma samples simultaneously [17]. Mass spectrometry in ESI (electrospray ionization) mode (API 5500; AB ScieX, Framingham, MA, USA) triple quadrupole system was used as the detector. Liquid chromatography and extraction method were created by Symbiosis Pro for Analyst (version 2.1.0.0) and submitted to the MS controlling software (Analyst 1.5.1). Meropenem and vancomycin concentrations in the collected plasma samples were determined by separate validated chromatographic assay methods. Meropenem and the internal standard (cefotaxime) were detected by ultraviolet absorbance at 304 nm. Vancomycin analysis was by liquid chromatography-tandem mass spectrometry on an Applied Biosystems API2000 (Applied Biosystems, Foster City, CA, USA) with Shimadzu autosampler (Shimadzu Corporation, Kyoto, Japan). Vancomycin and the internal standard (teicoplanin) were detected by positive-mode MRM (multiple reaction monitoring). All samples were assayed alongside calibration standards and quality control samples and met the acceptance criteria.

Statistical analysis

Linear mixed effects modeling was used to examine the change in concentration over time. This model accounts for the repeated responses from the same circuit by using a random intercept. The mixed effects model was fitted by using the R statistical software [18] version 2.13.2 and the ‘lme4’ library. The concentration-versus-time curves (mean ± standard error of the mean) were plotted by using GraphPad Prism version 5.03 (GraphPad Software, Inc., La Jolla, CA, USA).

Results

The ex vivo circuits were maintained under physiological conditions for 24 hours with no complications during the run. Four hundred samples (80 per drug) were analyzed. The changes in drug concentrations in the ex vivo model are summarized in Figures 1 and 2, and the actual drug concentrations determined in plasma samples from the control jars and the ECMO circuits are presented in Table 1. In this paper, only the data for fentanyl, morphine, midazolam, meropenem, and vancomycin are presented. Validated assays are being developed for the remaining study drugs, and the results will be made available in due course.

Testing confirmed that all baseline plasma samples were free of study drugs. There were no statistically significant differences in drug recoveries between the four circuits. The mean drug recoveries from the circuits and the control jars at 24 hours relative to baseline were, respectively, fentanyl 3% and 82%, morphine 103% and 97%, midazolam 13% and 100%, meropenem 20% and 42%, and vancomycin 90% and 99%. Up to 70% of fentanyl and 50% of midazolam were lost in the circuit within the first hour of ECMO run. Fentanyl levels were undetectable in the circuit by 24 hours. This may be related to the lipophilicity of these drugs. Morphine, which is less lipophilic than fentanyl, was stable in both the circuit and the controls. Antibiotics were less significantly affected. The hydrophilic and minimally protein-bound drug meropenem was stable in the circuit and the controls in the first 120 minutes, and 62% of the drug was recovered from the circuit at 6 hours. This was statistically significant ($P = 0.01$) even after accounting for spontaneous degradation (21%). There was no significant loss of the moderately protein-bound hydrophilic drug vancomycin in the circuit at 12 hours ($P = 0.41$) or 24 hours ($P = 0.26$).

Discussion

This is the first systematic investigation of drug disposition in the adult ECMO circuitry. The findings highlight the role of the circuit in altering the PK of sedative, analgesic, and antibiotic drugs during ECMO and clearly show that there is considerable between-drug variability in the degree of drug sequestration. Drugs that are unstable at physiological temperature (meropenem) and lipophilic drugs (fentanyl and midazolam) were more significantly affected. These findings may have significant implications for both the choice and the dosing of a particular drug prescribed during ECMO. Given the ongoing exteriorization of blood onto the circuit during ECMO, in vivo instability of drugs may also play a significant role in apparent PK during ECMO. By excluding the patient factors, this ex vivo model provides evidence that the adult ECMO circuit is not simply a benign conduit for blood but actively modulates drug PK.

The circuit factors were identical for all drugs. In this context, it is difficult to determine which of the drug factors contributed to the significant disparity in the degree of drug sequestration in the circuit and ex vivo stability. Differences in molecular size and lipophilicity and the differences in protein binding may all have contributed to the findings. This is important as a blanket increase in doses of all antibiotic drugs to avoid under-dosing without identifying the drugs that are most sequestered by the ECMO circuit may potentially result in drug toxicity. Similarly, drug sequestration in the circuit may also explain the increasing sedation requirements seen in patients on ECMO [8,9]. Using sedative and analgesic agents that are highly sequestered in the circuit may necessitate the use of very high doses of these drugs to
achieve the desired pharmacological effect and may add to the associated morbidity [6]. This calls for further research in this area to improve drug prescription during ECMO.

Given that meropenem and vancomycin both rely on time-dependent bacterial killing, the data presented here on altered antibiotic concentrations may be clinically relevant and require evaluation in a clinical PK study. Meropenem is degraded and sequestered significantly in the circuit beyond 4 to 6 hours. Hence, a more frequent dosing or use of higher doses may be required to maximize the time above minimum inhibitory concentration of the pathogen [19] as demonstrated in a recent clinical study [20]. Furthermore, administration of meropenem by infusion is questionable given the instability issues at room temperatures [21]. The utility of more stable carbapenem antibiotics such as doripenem may have to be explored in future studies. Clinically, there are no data on meropenem PK in patients receiving ECMO. Neonatal studies have uniformly shown an increase in Vd for vancomycin and a lower CL and consequently a longer vancomycin half-life [22,23]. Similarly, PK studies in neonates have shown increased Vd and decreased CL for morphine, midazolam, and their metabolites during ECMO [24,25]. The extent to which these PK alterations during ECMO are related to sequestration of these drugs in the circuit is currently unclear.

Studies in the neonatal ECMO circuits have demonstrated significant sequestration of sedative and antibiotic drugs in the circuit. Also, there is drug sequestration variability based on the different circuits, oxygenators, and pumps used [13]. A recent in vitro study [13] reported meropenem and vancomycin recovery of 89% and 67% at 180 minutes in neonatal circuits that used a centrifugal pump and polypropylene hollow-fiber membrane oxygenators. Whereas the meropenem recovery at 180 minutes is comparable to our results, vancomycin recovery was much lower in the neonatal circuits. In contrast, the fentanyl and midazolam circuit losses seen in this study are consistent with the results of the neonatal circuit studies [13,26-28]. Morphine appears to be relatively stable in both neonatal and adult ECMO circuits and may be the preferred analgesic during ECMO. Future clinical studies should compare the efficacy of different classes of drugs to rationalize sedation and analgesia during ECMO.

Studies that compare drug losses in clinically used versus new neonatal circuits have demonstrated significant variability in drug sequestration between the used and new circuits [10,13,28]. Consequently, it is still unclear whether there is saturation of the drug-binding sites in the ECMO circuit over time. Similarly, the effect

![Figure 1 Percentage of drug remaining in extracorporeal membrane oxygenation circuits and the controls plotted against time.](http://ccforum.com/content/16/5/R194)
of priming with various solutions on drug sequestration is not well characterized in the available literature. Drug sequestration in blood-primed circuits has been shown to be much lower than that in crystalloid-primed circuits [27]. It is possible that some of the blood components may compete with drugs for circuit-binding sites. Even though ECMO circuits are not routinely primed with blood prior to their use in adult patients, the circuits get primed with the patient’s own blood once ECMO is commenced.

In our study, we tried to replicate the clinical situation ex vivo which allowed us to study the interactions between the drug and the device in the absence of disease-related factors which independently can significantly alter PK [29,30]. Repeat dose experiments are required in long-term model systems to estimate the degree of circuit saturation with time. The concurrent presence of several other physically compatible study drugs in the circuit and control jars mimicked the clinical scenario in which patients receive these drugs concurrently, but the drugs may have had an impact on competitive binding to blood proteins or the circuit components. The presence of a reservoir bladder may have influenced the circuit drug losses. Similarly, quantification of drug lost in control jars because of binding of drugs to the polypropylene container was not feasible. However, the results confirm the findings of neonatal ECMO circuit studies.

**Conclusions**

This *ex vivo* study highlights the role of the ECMO circuit in altering PK during ECMO. These alterations are more pronounced for lipophilic drugs and may result in

---

**Table 1** Measured study drug concentrations in the control jars and the extracorporeal membrane oxygenation circuits at 5 minutes and at 1, 6, 12, and 24 hours

| Drug, units of concentration | 5 minutes | 1 hour | 6 hours | 12 hours | 24 hours |
|-----------------------------|-----------|--------|---------|----------|---------|
|                            | C         | E      | C       | E        | C       |
| Fentanyl, ng/mL             |           |        |         |          |         |
| Median                      | 27        | 1      | 25      | 0.4      | 26      | 0.1     | 22      | 0.1     | 22      | 0       |
| Range                       | 26-29     | 1-1    | 24-25   | 0.2-0.5  | 26-28   | 0-0.2   | 20-24   | 0-0.2   | 20-24   | 0-0.1   |
| Morphine, ng/mL             |           |        |         |          |         |
| Median                      | 136       | 7      | 139     | 8        | 137     | 8       | 139     | 8       | 135     | 8       |
| Range                       | 134-140   | 6-7    | 132-141 | 7-9      | 134-140 | 8-9     | 135-143 | 8-8     | 134-141 | 7-9     |
| Midazolam, ng/mL            |           |        |         |          |         |
| Median                      | 134       | 175    | 131     | 117      | 138     | 59      | 124     | 42      | 128     | 31      |
| Range                       | 126-155   | 144-356| 124-137 | 109-261  | 127-147 | 54-124  | 117-132 | 41-96   | 120-131 | 30-61   |
| Vancomycin, μg/mL           |           |        |         |          |         |
| Median                      | 71        | 73     | 70      | 73       | 72      | 71      | 72      | 71      | 69      | 67      |
| Range                       | 66-80     | 67-83  | 69-76   | 70-86    | 67-76   | 69-74   | 68-74   | 68-71   | 67-70   | 64-70   |
| Meropenem, μg/mL            |           |        |         |          |         |
| Median                      | 18        | 15     | 17      | 14       | 14      | 10      | 11      | 6       | 7       | 3       |
| Range                       | 17-18     | 11-16  | 16-18   | 10-15    | 13-15   | 7-11    | 11-11   | 4-8     | 7-8     | 2-5     |

C, control jars; E, extracorporeal membrane oxygenation circuits.
therapeutic failure. Morphine may be a useful alternative to fentanyl in a patient with escalating sedative and analgesic drug requirements. Less lipophilic sedative agents may have to be considered in patients receiving unusually high doses of midazolam. Given the instability issues and circuit sequestration, meropenem may have to be dosed more frequently or in higher doses pending future clinical PK studies. Vancomycin is less significantly affected, and therapeutic drug monitoring as currently practised can guide optimal treatment. PK studies in adult patients on ECMO are indicated for future research in order to generate the data to guide antibiotic, sedative, and analgesic therapy during ECMO.

**Key messages**

- Lipophilic drugs appear to be more significantly sequestered in the ECMO circuit, although further study with different lipophilic drugs is required to confirm this observation.
- Fentanyl and midazolam are more significantly sequestered than morphine.
- Meropenem may have to be administered more frequently during ECMO.
- Physical instability of meropenem may affect its delivery by a continuous infusion.
- Sequestration of drugs in the circuit may have implications on both the choice and dosing of a particular drug prescribed during ECMO.

**Abbreviations**

CL: clearance; ECMO: extracorporeal membrane oxygenation; PK: pharmacokinetics; PLS: permanent life support; Vd: volume of distribution.

**Acknowledgements**

This study was supported in part by funding provided by the National Health and Medical Research Council, the Australian and New Zealand College of Anaesthetists, the Intensive Care Foundation, The Prince Charles Hospital Foundation, and the Australian Red Cross Blood Service (the Blood Service) and Australian governments that fully fund the Blood Service for the provision of blood products and services to the Australian community. We thank Susie Parker-Scott for antibiotic drug assays and Lynnette Munck for assisting with revision of the manuscript.

**Author details**

1. Critical Care Research Group, Adult Intensive Care Services, The Prince Charles Hospital & The University of Queensland, Rode Road, Chermside, Queensland, Australia, 4032. 2. Burns Trauma and Critical Care Research Centre, The University of Queensland, Cnr Butterfield St and Bowen Bridge Rd, Herston, Queensland, Australia, 4029. 3. Institute of Health and Biomedical Innovation, School of Public Health & Social Work, Queensland University of Technology, Cnr Musik and Victoria Park Rd, Kelvin Grove, Queensland, Australia, 4059. 4. Centre for Integrated Preclinical Drug Development, Cnr Butterfield St and Bowen Bridge Rd Herston, The University of Queensland, Queensland, Australia, 4029.

**Authors’ contributions**

KS designed and coordinated the study, collected and analyzed data, and developed the manuscript for publication. CIM provided technical assistance in setting up the circuits. SF helped with procuring study drugs and dispensing them. AGB helped with statistical analysis. SG assayed study drugs midazolam, morphine, and fentanyl. SCW assisted with the control experiments and antibiotic drug assays. MTS and JAR helped with study design, data analysis, and manuscript preparation. DVM, YLF, and JFF assisted with study design, resources, and manuscript preparation. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

Received: 19 April 2012 Revised: 2 September 2012 Accepted: 18 September 2012 Published: 15 October 2012

**References**

1. Bartlett RH,Gattinoni L: Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiologica 2010, 76:534-540.
2. Kollef MH: Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000, 31(Suppl 4):S131-138.
3. Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
4. Roberts JA, Kruger P, Paterson DL, Lipman J: Antibiotic resistance--what’s dosing got to do with it? Crit Care Med 2008, 36:2433-2440.
5. Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, Roberts MJ, Kruger P, Lipman J: Antibiotic dosing in the ‘at risk’ critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 2011, 11:3.
6. Patel SB, Kress JP: Sedation and analgesia in the mechanically ventilated patient. Am J Respir Crit Care Med 2012, 185:486-497.
7. MacLaren G, Combès A, Bartlett RH: Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era. Intensive Care Med 2012, 38:210-220.
8. Shekar K, Mullany DV, Cowey A, Bull T, Fisquet S, Barnett AG, Roberts JA, Fraser JF: Increased sedation requirements in patients receiving extracorporeal life support for respiratory and cardio-respiratory failure. Anaesth Intensive Care 2012, 40:648-655.
9. Shekar K, Roberts JA, Ghassabian S, Mullany DV, Ziegenfuss M, Smith MT, Fung YL, Fraser JF: Sedation during extracorporeal membrane oxygenation—why more is less. Anaesth Intensive Care.
10. Bhatt-Mehta V, Annich G: Sedative clearance during extracorporeal membrane oxygenation. Perfusion 2005, 20:309-315.
11. Shekar K, Fraser JF, Smith MT, Roberts JA: Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012, 27:289-295.
12. Buck ML: Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet 2003, 42:403-417.
13. Wildschut ED, Ahmim MA, Allegraie KT, Mathot RA, Tibboel D: Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010, 36:2109-2116.
14. Roberts JA, Lipman J: Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851, quiz 859.
15. Alcorn J, McNamara PJ: Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003, 55:667-686.
16. Shekar K, Fung YL, Diab S, Mullany DV, McDonald CJ, Dunster KR, Fisquet S, Platt DQ, Stewart D, Walls SC, Smith MT, Roberts JA, Fraser JF: Development of simulated and ovine models of ECLS to improve understanding of circuit-host interactions. Crit Care Resusc 2012, 14:105-111.
17. Ghassabian S, Moosavi SM, Valero YG, Shekar K, Fraser JF, Smith MT: High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LC-MS/MS. J Chromatogr B Anal Tech Biomed Life Sci 2012, 903:126-133.
18. R Development Core Team: R: a language and environment for statistical computing, reference index version 2.13.2. Vienna, Austria: R Foundation for Statistical Computing, 2010 [http://www.R-project.org], ISBN 3-900051-07-0.
19. Varghese JM, Roberts JA, Lipman J: Pharmacokinetics and pharmacodynamics in critically ill patients. Curr Opin Anaesthesiol 2010, 23:472-478.
20. Shekar K, Roberts JA, Ghassabian S, Mullany DV, Wallis SC, Smith MT, Fraser JF: Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern? J Antimicrob Chemother.
21. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulken PM: Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010, 65:1073.
22. Mulla H, Pooboni S: Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005, 60:265-275.
23. Arnauter RD, DiPiro JT, Bhatia J: Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996, 40:1139-1142.
24. Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RA: Population pharmacokinetics of midazolam and its metabolites during venaovenarial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet 2010, 49:407-419.
25. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D: Morphine metabolite pharmacokinetics during venaovenarial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet 2006, 45:705-714.
26. Mulla H, Lawson G, von Anrep C, Burke MD, Upton DU, Firmin RK, Killer H: In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion 2000, 15:21-26.
27. Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH: Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med 2007, 33:1018-1024.
28. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Karen G: Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993, 15:263-266.
29. Lipman J, Udy AA, Roberts JA: Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth Intensive Care 2011, 39:999-1000.
30. Ulldemolins M, Roberts JA, Lipman J, Rello J: Antibiotic dosing in multiple organ dysfunction syndrome. Chest 2011, 139:1210-1220.

doi:10.1186/cc11679
Cite this article as: Shekar et al.: Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Critical Care 2012 16:R194.

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit